Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923504 | 0.99 | MAPT (0.49) | IDO1MAPTGRIN2BALDH1A1TP53 | |
| SCHEMBL1923580 | 0.87 | MAPT (0.50) | MAPTGRIN2BALDH1A1TP53 | |
| SCHEMBL1923825 | 0.87 | MAPT (0.38) | IDO1MAPTGRIN2B | |
| SCHEMBL1923726 | 0.86 | MAPT (0.51) | MAPTGRIN2BALDH1A1TP53L3MBTL1 | |
| SCHEMBL1923564 | 0.85 | PTGDR2 (0.42) | ALDH1A1 | |
| SCHEMBL1923990 | 0.84 | SMN1; SMN2 (0.45) | GRIN2BALDH1A1TP53TSHRL3MBTL1 | |
| SCHEMBL1923526 | 0.81 | MAPT (0.34) | MAPTALDH1A1GAA | |
| SCHEMBL1923983 | 0.80 | RAB9A (0.46) | MAPTALDH1A1L3MBTL1GAAHPGD | |
| SCHEMBL1923300 | 0.79 | USP10 (0.49) | MAPTGRIN2BALDH1A1TP53TSHR | |
| SCHEMBL1923398 | 0.79 | USP10 (0.49) | MAPTGRIN2BALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | claimed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | claimed |
| EP-2064185-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-06-03 | — | — | EP | claimed |
| WO-2008017710-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL S.A. (ES) | 2008-02-14 | — | — | WO | claimed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | claimed |
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | disclosed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| EP-2064185-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008017710-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | GABRA1, GABRA4, GABRA2 | IDO1 1338/4885MAPT 1569/4885GRIN2B 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.